CA2199642C - Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine - Google Patents

Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine Download PDF

Info

Publication number
CA2199642C
CA2199642C CA002199642A CA2199642A CA2199642C CA 2199642 C CA2199642 C CA 2199642C CA 002199642 A CA002199642 A CA 002199642A CA 2199642 A CA2199642 A CA 2199642A CA 2199642 C CA2199642 C CA 2199642C
Authority
CA
Canada
Prior art keywords
oligosaccharide
aspirin
sulpho
alpha
sulphoamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002199642A
Other languages
English (en)
Other versions
CA2199642A1 (fr
Inventor
Roger Cariou
Jacobus Christianus Johannes Stiekema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Akzo Nobel NV filed Critical Sanofi Synthelabo SA
Priority to CA002199642A priority Critical patent/CA2199642C/fr
Priority to EA199700025A priority patent/EA000048B1/ru
Priority to AU16319/97A priority patent/AU698456B2/en
Priority to BR9701313A priority patent/BR9701313A/pt
Publication of CA2199642A1 publication Critical patent/CA2199642A1/fr
Application granted granted Critical
Publication of CA2199642C publication Critical patent/CA2199642C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002199642A 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine Expired - Lifetime CA2199642C (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002199642A CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
EA199700025A EA000048B1 (ru) 1997-03-10 1997-03-13 Применение олигосахарида и аспирина для лечения тромбоэболических заболеваний, фармацевтическая композиция, способ лечения
AU16319/97A AU698456B2 (en) 1997-03-10 1997-03-14 Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt) 1997-03-10 1997-03-17 Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002199642A CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
AU16319/97A AU698456B2 (en) 1997-03-10 1997-03-14 Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt) 1997-03-10 1997-03-17 Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Publications (2)

Publication Number Publication Date
CA2199642A1 CA2199642A1 (fr) 1998-09-10
CA2199642C true CA2199642C (fr) 2001-05-08

Family

ID=27152254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199642A Expired - Lifetime CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine

Country Status (4)

Country Link
AU (1) AU698456B2 (fr)
BR (1) BR9701313A (fr)
CA (1) CA2199642C (fr)
EA (1) EA000048B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2564468B1 (fr) * 1984-05-16 1994-12-23 Choay Sa Nouveaux oligosaccharides, leur preparation par voie de synthese et leurs applications biologiques
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides

Also Published As

Publication number Publication date
EA000048B1 (ru) 1998-04-30
BR9701313A (pt) 1998-11-17
CA2199642A1 (fr) 1998-09-10
EA199700025A1 (ru) 1997-12-30
AU698456B2 (en) 1998-10-29
AU1631997A (en) 1998-09-17

Similar Documents

Publication Publication Date Title
RU2184547C2 (ru) Новые соединения действующих начал, содержащих клопидогрел, и антитромбическое средство
NO323739B1 (no) Preparater for behandling og forebygging av arteriell trombose og anvendelse av en faktor Xa inhibitor kombinert med et antiblodplateaggregeringsmiddel
Herbert et al. SR123781A, a synthetic heparin mimetic
US20060040896A1 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
EP1237559A1 (fr) Combinaisons pharmaceutiques
WO2000064470A1 (fr) Formulation pharmaceutique comportant un inhibiteur de thrombine de faible poids moleculaire et son promedicament
JP3813169B2 (ja) 抗血栓剤
Rogers et al. Current status of antithrombotic therapy in cardiovascular disease
Matsuo et al. Development of argatroban, a direct thrombin inhibitor, and its clinical application
Beijering et al. Clinical applications of new antithrombotic agents
CH661439A5 (it) Glicosaminoglicani modificati dotati di attivita antitrombotica.
CA2199642C (fr) Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
US20060122151A1 (en) Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin
JP3169343B2 (ja) アスピリンおよび抗−Ｘａオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Ｘａオリゴ糖の使用
US6828307B1 (en) Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity
MXPA97001943A (en) Compositions containing an acetilsalicilic acid association and an anti-xa oligosacarid and use of an anti-xa oligosacaride optionally in combination with acetilsalicil acid
KR100231978B1 (ko) 아스피린 회합체 및 안티-Xa 올리고사카라이드를 함유하는 조성물과 아스피린 결합물내 안티-XA 올리고사카라이드의 용도
Niada et al. Protective activity of defibrotide against lethal acute myocardial ischemia in the cat
Thiagarajan Antithrombotic Drugs
US20040214751A1 (en) Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
AU2001291549A1 (en) Antithrombotic compositions
AU2002363023B2 (en) A combination product comprising melagatran and dexamethasone
AU707215B2 (en) Thrombolytic agents
Perianu Clinical safety profile of cefodizime
CA2293081A1 (fr) Traitement medicamenteux de la restenose

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170310